Notwithstanding many setbacks, many MDM2 inhibitors have now progressed into late-phase clinical development. New procedures have also been designed to reinforce the efficacy of MDM2 inhibitors and to mitigate their on-focus on toxicity. In this evaluation, we summarize the progress and difficulties in the development of a MDM2 targeted therapy. https://mikhaily863ouy7.eedblog.com/profile